

A case of rheumatoid arthritis with a decrease in the serum concentration of soluble CD23 by traditional herbal medicine

Toshiaki KOGURE,* Atsushi NIIZAWA, Hiroshi FUJINAGA, Shinya SAKAI,
Le Xuan HAI, Yutaka SHIMADA, Katsutoshi TERASAWA

*Department of Japanese Oriental (Kampo) Medicine, Faculty of Medicine,
Toyama Medical and Pharmaceutical University*

(Received March 23, 1999. Accepted September 2, 1999.)

Abstract

Traditional herbal (Kampo) medicine for the treatment of rheumatoid arthritis (RA) has not been evaluated for changes in immune status during its use, although several anti-inflammatory effects have been studied *in vitro*. In this case report, we describe a 32-year-old Japanese female with RA who was effectively treated with the Kampo medicine, *Hochu-ekki-to* (Bu-Zhong-Yi-Qi-Tang, 補中益氣湯). This treatment decreased the serum concentration of soluble CD23 (sCD23) and RA activity, in addition to tumor necrosis factor- α .

These findings suggest that the therapeutic action of herbal medicine might be attributable to suppression of B cell activation.

Key words Kampo treatment, Immunomodulation, clinical course, case report.

Introduction

Traditionally, many kinds of Kampo formula have been used to treat patients with rheumatoid arthritis (RA) in China and also in Japan. In the last decade, the therapeutic effects have begun to be recognized by certain methods of evaluation in Western medicine.¹⁾ Additionally, the actions of Kampo formulae have been analyzed extensively.²⁻⁴⁾ Several ingredients contained in traditional herbs have been found to exert anti-inflammatory effects.⁵⁻⁷⁾ Recent study has shown that Kampo treatment suppresses the development of arthritis in a mouse model.⁸⁾ However, possible changes in immune status during RA treatment with herbal medicine have not been investigated.

Soluble CD23 molecule (sCD23) is often used as B cell activation marker to evaluate the status of autoimmune diseases.⁹⁻¹¹⁾ We demonstrated that

serum levels of sCD23 are elevated correlated with the levels of IgM-rheumatoid factor (IgM-RF) in patients with RA.¹¹⁾ This molecule enhances the interferon- γ -induced release of tumor necrosis factor- α (TNF- α) from monocytes.¹²⁾

Here, we present a case of RA showing a decrease in serum concentration of soluble CD23, as well as improvement in the joint symptoms, by the Kampo formula *Hochu-ekki-to* (Bu-Zhong-Yi-Qi-Tang, 補中益氣湯).¹³⁾

Case report

A Japanese woman developed polyarthralgia, particularly in the bilateral knee joints, in April 1985 at the age of 24. Subsequently, she complained of bilateral wrist and elbow joint pain. She was examined at a nearby hospital, found to have IgM-RF, and was diagnosed with RA. She was treated with 15 mg/day of prednisolone (PSL) and 240 mg/day of

*〒930-0194 富山市杉谷2630

富山医科薬科大学医学部と漢診療学教室 小暮敏明
2630 Sugitani, Toyama 930-0194, Japan

Table I Kampo formulae used in the treatment for the present patient

Kampo formulae	Components	Indications*
Hochu-ekki-to (Bu-Zhong-Yi-Qi-Tang)	Astragali Radix 4.0 Ginseng Radix 4.0 Bupleuri Radix 2.0 Aurantii Nobilis Pericarpium 2.0 Cimicifugae Rhizoma 1.0 Atractylodis Lanceae Rhizoma 4.0 Angelicae Radix 3.0 Zizyphi Fructus 2.0 Glycyrrhizae Radix 1.5 Zingiberis Rhizoma 0.5	Weak physical condition during recovery, tuberculosis, anemia, loss of appetite, mild fever, dysfunction of the digestive system
Toki-shakuyaku-san (Dang-Gui-Shao-Yao-San)	Paeoniae Radix 4.0 Atractylodis Lanceae Rhizoma 4.0 Alismatis Rhizoma 4.0 Angelicae Radix 3.0 Hoelen 4.0 Cnidii Rhizoma 3.0	Especially correspondent for girls and women with weak physical constitution, anemia, mild edema, weakness of muscles, fatigue, dysmenorrhea, conditions pathologic during pregnancy and after delivery
Keishi-ni-eppi-itto-ka-ryojutsubu (Gui-Zhi-Er-Yue-Bi-Yi-Tang-Jia-Ling-Zhu-Fu)	Cinnamomi Cortex 2.5 Paeoniae Radix 2.5 Glycyrrhizae Radix 2.5 Ephedrae Herba 2.5 Zingiberis Rhizoma 3.5 Zizyphi Fructus 3.0 Gypsum Fibrosum 3.0 Hoelen 3.0 Atractylodis Lanceae Rhizoma 3.0 Aconitii Tuber 1.0	Physically weak patients, red face, cold feet, pain of joints and muscles accompanied by sweating morning stiffness of finger joints, edema, oliguria
Kyuki-choketsu-in (Xong-Gui-Tiao-Xue-Yin)	Angelicae Radix 2.0 Cnidii Rhizoma 2.0 Rhemanniae Radix 2.0 Atractylodis Rhizoma 2.0 Hoelen 2.0 Aurantii Nobilis Pericarpium 2.0 Aconiti Tuber 2.0 Moutan Radix 2.0 Cyperi Rhizoma 2.0 Zizyphi Fructus 1.5 Zingiberis Siccatum Rhizoma 1.0 Glycyrrhizae Radix 1.0 Leonuri Herba 1.5	Exhaustion, dysmenorrhea, neurosis after a delivery, weakness, pale face, palpitation, sleeplessness
Toki-shigyaku-ka-goshuyu-shokyo-to (Dang-Gui-Si-Ni-Jia-Wu-Zhu-Yü-Sheng-Jiang-Tang)	Zizyphi Fructus 5.0 Cinnamomi Cortex 3.0 Paeoniae Radix 3.0 Angelicae Radix 3.0 Akebiae Caulis 3.0 Glycyrrhizae Radix 2.0 Evodiae Fructus 2.0 Asiasari Radix 2.0 Zingiberis Rhizoma 1.0	Cold hands and feet, pain in the limbs, pain in the lower abdomen, headache, weak patients, painful scars

*Indications show the target group according to the method of traditional herbal medicines.¹⁰⁾

lobenzarit disodium (LD), and her polyarthralgia improved.

In 1987, the patient presented herself at our institution requesting treatment with traditional herbal (Kampo) medicine. We treated her with *Keishi-ni-eppi-itto-ka-ryojutsubu* (Gui-Zhi-Er-Yue-Bi-Yi-Tang-Jia-Ling-Zhu-Fu, 桂枝二越婢一湯加苓朮附), *Kyuki-choketsu-in* (Xong-Gui-Tiao-Xue-Yin, 芎歸調血飲) or *Toki-shigyaku-ka-goshuyushokyo-to* (Dang-Gui-Si-Ni-Jia-Wu-Zhu-Yü-Sheng-Jiang-Tang, 當歸四逆加吳茱萸生薑湯) (Table I) in addition to PSL and LZ. Kampo treatment resulted in a decrease in the serum inflammatory reaction as well as arthralgia. Thus, in December of that year, we discontinued LD and reduced the dosage of PSL from 10 mg/day to 7.5 mg/alternative day. Thus, in June 1988, PSL was discontinued. Subsequently, arthralgia was localized to the right elbow joint, and C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) remained low (CRP 0.3-0.5 mg/dl, ESR 8-25 mm/hour).

In January 1993, the patient gave birth. In June of that year, she suffered from bilateral wrist pain again, and subsequently experienced bilateral gonalgia. By June 1994, morning stiffness lasted about ten minutes, grip strength was 180 mmHg on the right and 210 mmHg on the left, and joint counts were 32 points.¹⁴⁾ Lansbury activity index¹⁵⁾ was 35 % and her status of

RA was stage II, Class 2 at that time. There were no abnormal findings in the chest or abdomen. Her laboratory findings are shown in Table II. The CRP and ESR levels increased from her baseline and anti-nuclear antibody (ANA) was present. We considered her condition to represent progression of RA disease activity, and she was treated with Kampo formula, *Hochu-ekki-to*, which was selected according to the diagnostic method of traditional herbal medicine.¹³⁾ The selection of this formula was based on her general malaise and geographic tongue, suggesting a KI deficiency. Before administration of this formula, we treated her with *Toki-shakuyaku-san* (Dang-Gui-Shao-Yao-San, 當歸芍藥散), but the serum concentration of CRP had increased. Figure 1 shows the patient's clinical course. Kampo formula *Hochu-ekki-to* resulted in improvement in her symptoms, and her serum CRP was 1.0 mg/dl and ESR 36 mm/Hour in November 1994. RAHA titer changed from 640x to 320x in September although its titer remained 640x before September. As of June 1994, she had not taken any DMARDs.

To investigate the immune status of this patient, we measured the serum concentrations of soluble CD23 (sCD23) and TNF- α by antibody sandwich enzyme-linked immunosorbent assays (ELISA) using commercial kits (sCD23: T-cell Diagnostics, Inc.,

Table II Laboratory findings in June 1994

WBC	10340 /mm ³	LDH	143 IU/L		
Neut	72.1 %	GOT	15 KU	ESR	51 mm/hr
Eos	1.2 %	GPT	11 KU	CRP	2.5 mg/dl
Baso	1.1 %	γ -GTP	14 IU/L	IgG	2056 mg/dl
Lymph	18.5 %	ALP	236 IU/L	IgM	275.8 mg/dl
Mono	5.7 %	T-BIL	0.4 mg/dl	IgA	467.6 mg/dl
RBC	460 $\times$ 10 ⁴ /mm ³	CH-E	0.84 Δ pH	RAHA§	640 $\times$
Hb	9.9 g/dl	T-Cho	180 mg/dl	ANA*	160 (Sp) $\times$
PLT	48.4 $\times$ 10 ⁴ /mm ³	TG	91 mg/dl	CH ₅₀	43 U/ml
TP	8.0 g/dl	Na	139 mEq/L	aDNA ab**	negative
Alb	4.1 g/dl	K	3.8 mEq/L	aSS-A/Ro ab#	negative
Alb	55.1 %	Cl	105 mEq/L	aSS-B/Ro ab	negative
α_1 -glob	3.3 %	BUN	6 mg/dl		
α_2 -glob	8.9 %	Cr	0.4 mg/dl	Urinalysis	WNL
β -glob	10.7 %	UA	2.8 mg/dl	Chest X-ray	WNL
γ -glob	21.6 %				

*Anti-nuclear antibody **anti-DNA antibody #anti SS-A/Ro antibody
§rheumatoid arthritis hemagglutination




Figure 1 Clinical course and serological data after June 1994. Kampo treatment resulted in a decrease in symptoms, and her serum CRP was 1.0 mg/dl and ESR 36 mm/Hour in November 1994. The serum concentration of sCD23 remained high until September 1994, but its concentration decreased in October. Serum TNF- α concentration gradually decreased after the administration of Hochu-ekki-to. The finding from healthy subjects ; sCD23 : 63.4 ± 21.5 U/ml, TNF- α : 17.4 ± 8.6 pg/ml, respectively. TNF- α : Tumor necrosis factor- α , CRP : C-reactive protein, ESR : Erythrocyte sedimentation rate.

Cambridge, MA ; TNF- α : Boehringer Mannheim Biochemica, Germany). sCD23 was expressed in U/ml, and TNF- α in pg/ml. The detection limits were 15 U/ml and 10 pg/ml for sCD23 and TNF- α , respectively. As a control, sera from 20 healthy volunteers were used. Serum samples were stored at -20°C until use. The finding from healthy subjects were ; sCD23 : 63.4 ± 21.5 U/ml, and TNF- α : 17.4 ± 8.6 pg/ml. As shown in Fig. 1, the patient's sCD23 concentration changed from 365 U/ml in July to 237 U/ml in October 1994. After that, the concentration remained in the 280–300 U/ml range. Serum TNF- α concentration gradually decreased after the administration of Hochu-ekki-to. Its concentration changed from 108 pg/ml to 18.5 pg/ml.

Discussion

Since the beginning of the 20th century, Western medicine has made rapid progress and many patients have been able to escape from pain. However, it is a fact that not all patients are satisfied with Western

medicine. In Japan, about one-third of RA patients take alternative medicines.¹⁶⁾

There are high expectations concerning the efficacy of these agents in the treatment of RA in Japan. These treatments are excellent in terms of safety, based on their use over thousands of years, and they may be administered continuously over several years. Many RA patients in Japan have been treated effectively with Kampo formulae.¹⁷⁾ In our previous study we demonstrated the effectiveness of *Keishi-ni-eppitto-ka-ryojutsubu* for RA by open trial.¹⁾ Additionally, the action of Kampo formula or single herb is also being clarified.²⁻⁷⁾ However, whether there are changes in the immune status during treatment with herbal medicine for RA has not been established, although anti-inflammatory effects have been studied *in vitro*. Thus, in the present case study, we investigated the state of the immune system during Kampo treatment for RA.

For this patient, *Hochu-ekki-to* was effective in treating arthralgia by decreasing the levels of the classic inflammatory parameters—CRP and ESR. The

serum concentration of sCD23 remained high until September 1994, but its concentration decreased in October (Fig. 1). The change in sCD23 concentration was similar to that of RAHA titer, but not CRP concentration. CD23 molecule is expressed by peripheral blood B lymphocytes and several lymphoblastoid B cell lines.¹⁸⁾ This molecule was expressed at high levels by Epstein-Barr virus-transformed cells, and has thus been regarded as a B cell activation marker.¹⁹⁾ This surface antigen is continuously cleaved into soluble fragments, which are called soluble CD23.²⁰⁾ Clinically, serum levels of sCD23 are elevated in primary Sjögren's syndrome, systemic lupus erythematosus and RA, and are correlated with the levels of IgM-RF in patients with RA.⁹⁻¹¹⁾ Thus, sCD23 molecule is suitable for evaluating the immune status of RA patients. In the present case the serum concentration of sCD23 decreased, suggesting that Kampo treatment might suppress B cell activation in parallel with the anti-inflammatory effect. Recently, it has been demonstrated that sCD23 molecule enhances the interferon- γ -induced release of TNF- α from monocytes.¹²⁾ Thus, we also measured the serum concentration of TNF- α , and as shown in Fig. 1, its concentration also decreased. These findings suggest that this Kampo formula has anti-inflammatory effects and immunomodulatory effects, including suppression of B cell activation. Non-steroidal anti-inflammatory drugs (NSAIDs) did not suppress the production of IgG and IgA from peripheral blood mononuclear cells,²¹⁾ indicating that the actions of Kampo formulae do not equal those of NSAIDs.

We found a decrease in serum sCD23 concentration in a patient with RA and concluded that part of the therapeutic effect might be dependent on the suppression of B cell activation. We have not performed *in vitro* analyses such as those done on lobenzarit or bucilamine.^{22, 23)} The reason for this is that a Kampo formula is a crude drug, and it is possible that unknown ingredients are contained in a water extract, therefore, such components may not always be absorbed into the intestine. In other words, it can not be ruled out that the action recognized in *in vitro* analysis results from an ingredient that is not detected in peripheral blood. Thus, it is important to clinically evaluate the immune status of the patient.

Finally, this is the first evaluation of changes in immune status during Kampo treatment. Kampo therapy resulted in a decrease in serum sCD23 concentration, as well as a decrease in RA disease activity, suggesting that its therapeutic effect might be attributable to suppression of B cell activation.

Supplementary notes

All Kampo formulae used for this patient were hot water extracts that were prepared from a mixture of several dried traditional herbal medicines. The mixture of dried herbal medicines was mixed in 600 ml of water and reduced to 300 ml. The aqueous extract, called the "decoction", was taken 3 times a day before meals. The components and indications for each Kampo formula are summarized in Table I.

Acknowledgement

This work was supported in part by a grant for research in Japanese Oriental Medicine & Biotechnology from the Toyama Prefectural Government.

和文抄録

和漢薬治療は慢性関節リウマチ (RA) に対して極めて有用な治療法であるが、その作用機序に関しては、In Vitro による生薬の抗炎症効果は解析されているものの、In Vivo での免疫学的な評価はいまだ未着手な部分が多い。われわれは補中益気湯などが有効であった RA の一例を経験した。この患者は、RA の疾患活動性の低下に加えて血清中可溶性 CD23 (sCD23) が低下し、さらに、血清 TNF- α 濃度も、漸次低下していた。このことから RA の治療において和漢薬は単に抗炎症効果を有するだけでなく Immunomodulator として作用している可能性が示唆された。その一部として RA 患者での B 細胞の活性化を抑制している可能性がある。

References

- 1) Kogure, T., Itoh, T., Shimada, Y., Takahashi, K., Terasawa, K.: The influence of a traditional herbal medicine on the disease activity in patients with rheumatoid arthritis. *Clin Rheumatol Rel Res* 8, 233-241, 1996.
- 2) Hirabayashi, T., Ochiai, H., Sakai, S., Nakajima, K., Terasawa, K.: Inhibitory effect of ferulic acid and isoferulic acid on murine

- interleukin-8 production in response to influenza virus infections *in vitro* and *in vivo*. *Planta Med* **61**, 221-226, 1995.
- 3) Cuellar, MJ., Giner, RM., Recio, MC., Just, MJ., Manez, S., Cerds, S., Rios, JL. : Screening of anti-inflammatory medicinal plants used in traditional medicine against skin disease. *Phytother Res* **12**, 18-23, 1998.
 - 4) Hamasaki, Y., Kobayashi, I., Hayasaki, R. *et al.* : The Chinese herbal medicine, shinpi-to, inhibits IgE-mediated leukotriene synthesis in rat basophilic leukemia-2H3 cells. *J Ethnopharmacol* **56**, 123-131, 1997.
 - 5) Takahashi, K., Kobayashi, H., Kobayashi, S., Kimura, I., Terasawa, K., Kimura, M. : Antiproliferative effects of magnosalin derived from 'shin'i' (Flos magnoliae), a Japanese Sino-medicine, on cultured synovial cells of MRL/1 and C57BL/6J mice. *Phytother Res* **10**, 42-48, 1996.
 - 6) Chang, D-M., Chang, W-Y., Kuo, S-Y., Chang, M-L. : The effects of traditional antirheumatic herbal medicines on immune response cells. *J Rheumatol* **24**, 436-441, 1997.
 - 7) Tao, X., Schulze-Koops, H., Ma, L., Cai, J., Mao, Y., Lipsky, PE. : Effects of tripterygium wilford II hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. *Arthritis Rheum* **41**, 130-138, 1998.
 - 8) Wakabayashi, K., Inoue, M., Ogiwara, Y. : The effect of Keishibushi-to on collagen-Induced arthritis. *Biol Pharm Bull* **20**, 376-380, 1997.
 - 9) Morimoto, S., Tokano, Y., Takasaki, Y., Hashimoto, H. : Relation between the levels of soluble CD4, CD8 and CD23 molecules in sera and clinical manifestations and laboratory data in patients with systemic lupus erythematosus. *Jpn J Rheumatol* **71**, 301-308, 1996.
 - 10) Bansal, A., Roberts, T., Hay, EM., Kay, R., Pumphrey, RSH., Wilson, PB. : Soluble CD23 levels are elevated in the serum of patients with primary sjögren's syndrome and systemic lupus erythematosus. *Clin Exp Immunol* **89**, 452-455, 1992.
 - 11) Kogure, T., Itoh, T., Shimada, Y., Shintani, T., Ochiai, H., Terasawa, K. : Detection of serum soluble markers of immune activation in rheumatoid arthritis. *Mediat Inflamm* **5**, 262-265, 1996.
 - 12) Armant, M., Ishihara, H., Rubio, M., Delespesse, G., Sarfati, M. : Regulation of cytokine production by soluble CD23 : costimulation of interferon γ secretion and triggering of tumor necrosis factor α release. *J Exp Med* **180**, 1005-1011, 1994.
 - 13) Terasawa, K. : Introduction. In "KAMPO Japanese-Oriental Medicine", Insights from Clinical Cases. K.K. Standard McIntyre, Tokyo, p.2, 1993.
 - 14) Kotaniemi, A., Isomaki, H., Hakala, M., Cai, J., Mao, Y., Lipsky, PE. : Increased type I collagen degradation in early rheumatoid arthritis. *J Rheumatol* **21**, 1593-1596, 1994.
 - 15) Lansbury, J. : Method for evaluating rheumatoid arthritis. In "Arthritis and allied conditions (JL Hollander, Ed)", 7. Lea & Febiger, Philadelphia, p.269, 1966.
 - 16) Shiokawa, Y. : Rheumatology, and medicine in the 21st Century. *The Ryumachi* **37**, 600-606, 1997 (in Japanese).
 - 17) Imadaya, A. : Text Book : Kampo treatment for rheumatoid arthritis. In Case Study : 22-87, Gendaishuppan planning, Tokyo, 1994 (in Japanese).
 - 18) Lawrence, DA., Weigle, WO., Spiegelberg, HL. : Immunoglobulins cytophilic for human lymphocytes, monocytes, and neutrophils. *J Clin Invest* **55**, 368-387, 1975.
 - 19) Kintner, C., Sugden, B. : Identification of antigenic determinants unique to the surfaces of cells transformed by Epstein-Barr virus. *Nature* **294**, 458-460, 1981.
 - 20) Lee, BW., Simmons, CF. Jr., Wileman, T., Geha, RS. : Intracellular cleavage of newly synthesized low affinity Fc epsilon receptor (Fc epsilon R2) provides a second pathway for the generation of the 28-kDa soluble Fc epsilon R2 fragment. *J Immunol* **142**, 1614-1620, 1989.
 - 21) Al-Balaghi, S., Strom, H., Moller, E. : Effect of drug therapy on circulating and synovial fluid Ig-secreting cells in rheumatoid arthritis. *Ann Rheum Dis* **44**, 232-238, 1985.
 - 22) Hirohata, S., Shinohara, S., Inoue, T., Miyamoto, T., Lipsky, PE. : Regulation of B cell function by lobenzarit, a novel disease-modifying antirheumatic drug. *Arthritis Rheum* **35**, 168-175, 1992.
 - 23) Hirohata, S., Lipsky, PE. : Regulation of B cell function by bucillamine, a novel disease-modifying antirheumatic drug. *Clinical Immunol Immunopathol* **66**, 43-51, 1993.